KalVista Pharmaceuticals (KALV) Liabilities and Shareholders Equity (2014 - 2025)

KalVista Pharmaceuticals (KALV) has 12 years of Liabilities and Shareholders Equity data on file, last reported at $215.5 million in Q3 2025.

• For the quarter ending Q3 2025, Liabilities and Shareholders Equity rose 7.65% year-over-year to $215.5 million; the trailing twelve-month figure through Jul 2025 stood at $921.9 million (up 33.94% YoY), and the FY2025 full-year result was $250.8 million, up 6.53% from the prior year.
• Liabilities and Shareholders Equity retreated to $215.5 million in Q3 2025, from $250.8 million in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $294.8 million in Q4 2024 to a low of $66.2 million in Q1 2021.
• A 5-year average of $198.6 million and a median of $203.5 million in 2023 frame the typical range for Liabilities and Shareholders Equity.
• Across the five-year window, Liabilities and Shareholders Equity soared 239.93% in 2022 and slumped 43.99% in 2024, its largest moves.
• Tracing KALV's Liabilities and Shareholders Equity over 5 years: stood at $243.8 million in 2021, then slumped by 33.21% to $162.8 million in 2022, then dropped by 14.8% to $138.7 million in 2023, then jumped by 112.49% to $294.8 million in 2024, then declined by 26.9% to $215.5 million in 2025.
• Business Quant data shows KALV's Liabilities and Shareholders Equity at $215.5 million in Q3 2025, $250.8 million in Q2 2025, and $294.8 million in Q4 2024.